The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.

ABSTRACT:

Background

This meta-analysis aimed to investigate the efficacy of immune checkpoint inhibitor (ICI)-based therapy in non-small cell lung cancer (NSCLC) patients with different clinical and molecular characteristics such as age, sex, histological type, performance status (PS), smoking status, driver mutations, metastatic site, region and number of prior systemic regimens.

Methods

A systematic literature search was conducted in PubMed, Embase, and the Cochrane library databases to identify qualified randomized controlled trials (RCTs). The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS).

Results

A total of 19 RCTs were included in this meta-analysis. ICI-based therapy significantly improved OS compared with non

SUBMITTER: Xu Y 

PROVIDER: S-EPMC8453160 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature